U
VRTX icon

UBS’s Vertex Pharmaceuticals VRTX Stock Holding History

UBS’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$180K Sell
1,600
-30,900
-95% -$2.94M ﹤0.01% 5296
2014
Q2 		$3.08M Buy
32,500
+21,100
+185% +$1.48M ﹤0.01% 2445
2014
Q1 		$806K Buy
11,400
+8,800
+338% +$697K ﹤0.01% 3711
2013
Q4 		$193K Buy
2,600
+500
+24% +$34.8K ﹤0.01% 5328
2013
Q3 		$159K Sell
2,100
-14,100
-87% -$1.12M ﹤0.01% 5472
2013
Q2 		$1.3M Buy
+16,200
New +$1.19M ﹤0.01% 3025

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

UBS's VRTX Position: Q3 2014 in Review

UBS increased its Vertex Pharmaceuticals (VRTX) stake by 18% in Q3 2014, buying an estimated $4.48M and bringing the position to 307,532 shares worth $34.5M. The position accounts for 0.03% of the portfolio, ranked #666.

UBS first reported a position in VRTX in Q2 2013 and has held it in 6 quarters since. 430 funds tracked by Wall St. Rank hold VRTX as of Q3 2014.

  • UBS held 307,532 shares of Vertex Pharmaceuticals worth $34.5M as of Q3 2014.
  • UBS bought 47,028 Vertex Pharmaceuticals shares in Q3 2014, an estimated $4.48M.
  • Vertex Pharmaceuticals made up 0.03% of UBS's portfolio in Q3 2014, its #666 holding.
  • UBS first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
  • 430 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.